

a4 99. (Amended) The method of claim[s] [91- 96] 91, further comprising co-administering a substrate of endothelial cell Nitric Oxide Synthase.

a5 103. (Amended) The method of claim[s] [91- 96] 91, further comprising co-administering at least one different HMG-CoA reductase inhibitor that increases endothelial cell Nitric Oxide Synthase activity.

a6 108. (Amended) The method of claim[s] [91- 96] 91, further comprising co-administering at least one different HMG-CoA reductase inhibitor in an amount effective to increase endothelial cell Nitric Oxide Synthase activity in said tissue of the subject.

a7 177. (Amended) The method of claim[s] [167-174] 167, further comprising co-administering a substrate of endothelial cell Nitric Oxide Synthase.

a8 181. (Amended) The method of claim[s] [167-174] 167, further comprising co-administering at least one different HMG-CoA reductase inhibitor that increases endothelial cell Nitric Oxide Synthase activity.

182. (Amended) The method of claim[s] [167-174] 167, further comprising co-administering at least one different HMG-CoA reductase inhibitor in an amount effective to increase endothelial cell Nitric Oxide Synthase activity in said tissue of the subject.

a9 187. (Amended) The method of claim[s] [167-174] 167, further comprising co-administering a second agent to the subject with a condition treatable by the second agent in an amount effective to treat the condition, whereby the delivery of the second agent to a tissue of the subject is enhanced as a result of the increased blood flow.

a10 192. (Amended) The method of claim[s] [167-174] 168, further comprising co-administering a second agent to the subject with a condition treatable by the second agent in an amount effective to treat the condition, whereby the delivery of the second agent to the brain of the subject is enhanced as a result of the increased blood flow.

193. (Amended) The method of claim[s] [167-174] 167, further wherein the tissue is brain and the
second agent comprises an agent having a site of action in the brain.

Respectfully submitted,

Edward R. Gates

Edward R. Gates, Reg. No. 31,616
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, MA 02210-2211
(617)720-3500

Docket No. R0547/7007(ERG/KA)
Dated: July 28, 1999